Journal Logo

You can read the full text of this article if you:

Institutional members access full text with Ovid®

Feature Articles

Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)*

Hotchkiss, Richard S. MD1; Colston, Elizabeth MD, PhD2; Yende, Sachin MD3,4; Angus, Derek C. MD, MPH4; Moldawer, Lyle L. PhD5; Crouser, Elliott D. MD6; Martin, Greg S. MD, MSc, FCCM7; Coopersmith, Craig M. MD8; Brakenridge, Scott MD, MSCS5; Mayr, Florian B. MD, MPH3,4; Park, Pauline K. MD9; Ye, June PhD2; Catlett, Ian M. PhD2; Girgis, Ihab G. PhD2; Grasela, Dennis M. PharmD, PhD2

Author Information
doi: 10.1097/CCM.0000000000003685
  • Buy
  • SDC
  • Editor's Choice

Abstract

Copyright © 2019 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.